Alpha Profiles · Company Profile

Gossamer Bio, Inc.

https://registry.alpha.ac/companies/gossamer-bio-inc

Entity: Public listing published
Primary listing: NASDAQ: GOSS
Verification: Partially verified
Last reviewed: 2026-10-08T04:46:49.803725+00:00

Overview

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

5 public records

Bryan Giraudo

Chief Financial Officer and Chief Operating Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001728117-26-000027Apr 24, 2026

Caryn Peterson

Executive Vice President, Regulatory

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001728117-26-000027Apr 24, 2026

Christian Waage

Executive Vice President, Technical Operations and Administration

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001728117-26-000027Apr 24, 2026

Faheem Hasnain

President and Chief Executive Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001728117-26-000027Apr 24, 2026

Robert Smith

Chief Commercial Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001728117-26-000027Apr 24, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Oct 8, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.